BioSig Technologies Inc. Reports Increased Adoption of its Signal Processing Technology for Arrhythmia Care

Photo provided by BioSig

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

BioSig Technologies Inc. BSGM, a medical technology company commercializing an innovative signal-processing platform designed to improve signal fidelity and uncover the full range of electrocardiogram (ECG) and intracardiac signals, today announced that it exceeded its procedural target of 1,500 patient cases in 2021.

As of Oct. 21, the PURE EP™ System had been used in more than 1,560 patient cases by 71 physicians, up from 1,000 cases in June when the procedural guidance was raised amid increased technology use in elective procedures. As the adoption of the technology increases and the COVID-19 hospitalization rates continue to decline, the company intends to complete between 1,700 and 1,800 procedures by the end of 2021.

Following this news, BioSig announced it is installing a PURE EP System for an evaluation at the Beth Israel Deaconess Medical Center (BIDMC) in Boston, MA. BioSig is also installing the PURE EP System for an evaluation at the Methodist Hospital in San Antonio, TX, one of the largest hospitals in the United States in terms of the number of available beds. These 90 day  evaluation agreements bring the Company up to 16 installed centers.

Physicians recognize value both clinically and economically, or they would not be increasing their usage. Hospitals are rapidly scaling their elective procedures, and thus we are now seeing increased case volumes and commercial activity,” said Kenneth L. Londoner, BioSig’s chairman and CEO.

Clinical data acquired by the PURE EP System in a multicenter study showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP signals over conventional sources. The study can be viewed electronically at Wiley Online Library. 

About BioSig Technologies

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal-processing platform designed to improve signal fidelity and uncover the full range of ECG and intracardiac signals.

The company’s 1st product, the PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

More on the PURE EP System 

PURE EP provides distinctive signal information to guide key clinical decisions. In a recent blind study, EPs rated PURE EP as equivalent or superior to conventional systems for 93.6% of signal samples, with 75.2% earning a superior rating.

By improving the comprehensiveness and readability of standard electrophysiology procedures, BioSig Technologies says it can help spot and prevent cardiac arrests and arrhythmias — 2 major worldwide health problems that account for 15 to 20% of all deaths.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.